Skip to content

A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder.

A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder. - A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032555
Enrollment
120
Registered
2019-08-31
Start date
2018-05-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Intake of capsules containing noni fruit powder for 12 weeks. Intake of capsules non-containing noni fruit powder (placebo) for 12 weeks.

Sponsors

Soiken Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The subject who meets all the conditions in a screening test 1) Subject whose age of 20 years or more and less than 55 years at the time of informed consent. 2) Subject whose BMI is 25 kg/m2 or more and less than 30 kg/m2. 3) Subject who is received sufficient explanation about purpose and content of this exam and have the capacity to consent and voluntarily write participation agreement in this examination voluntarily participate after understanding well.

Exclusion criteria

Exclusion criteria: 1) Subject who has a mental disease such as depression, schizophrenia, epilepsy and bulimia nervosa. 2) Subject who has allergic disease, cardiovascular, respiratory, thyroid gland malfunction, diabetes, heart disease, heart disease, gout or sleep disorder. 3) Subject who takes regularly medicinal drugs or medicines having an effect on the weight. 4) Subject who has the possibility of developing allergic symptoms by the test food (noni allergy). 5) Subject who has a snacking habit that influence the evaluation of the effects of the test food. 6) Female subject who is pregnant or may be pregnant during the study. 7) Female subject who is in the lactation during the study. 8) Subject who took blood samples of 200 ml or more within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood). 9) Subject who participated in other clinical trials within the past 4 months or currently participating in other clinical trials or planning to participate in other clinical trials during the examination period. 10) Subject deemed unsuitable by the investigator.

Design outcomes

Primary

MeasureTime frame
body weight, BMI

Secondary

MeasureTime frame
waist circumference, visceral fat area, body fat percentage, total fat area

Countries

Japan

Contacts

Public ContactTomohiro Sugino

Soiken Inc. R&D Division

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026